Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 Buyback Yield % is 0.00 as of Aug. 04, 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 279 Drug Manufacturers companies, Sudeep Pharma ranks worse than 358422.58% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Sudeep Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a Buyback Yield % of 0.00 as of Aug. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #999999 out of 279 companies in the Drug Manufacturers industry.
Is Sudeep Pharma's Buyback Yield % too high?
Sudeep Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, Sudeep Pharma ranks #999999 out of 279 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #999999 out of 279 companies for Buyback Yield %. This places Sudeep Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sudeep Pharma and its competitors. Sudeep Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Buyback Yield % is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
